Vericel Corporation (VCEL) Stock Analysis & Investment Frameworks
Vericel Corporation (VCEL) stock analysis on Invetso. Review Vericel Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Vericel Corporation Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Vericel Corporation Key Financial Metrics
- Market Cap: $2.08B
- Revenue: $276.26M
- P/E Ratio: 126.85
- ROE: 6.91%
- ROIC: 3.79%
- Dividend Yield: N/A
About Vericel Corporation
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Vericel Corporation Investment Frameworks
Invetso analyzes Vericel Corporation (VCEL) across the following frameworks:
- Vericel Corporation 10Y Growth Potential
- Vericel Corporation Scenario Analysis
- Vericel Corporation Risks & Opportunities
- Vericel Corporation Economic Moat
- Vericel Corporation Business Model
- Vericel Corporation Management
- Vericel Corporation SWOT Analysis
- Vericel Corporation Porter's 5 Forces
- Vericel Corporation PESTLE Analysis
- Vericel Corporation ESG Analysis